Pfizer is developing a pastilla to cope with covid-19 infection. This is in an advanced stage and the company expects to have it ready in 2021.
The American pharmaceutical company sees a market of more than 150 million people in the world who could access the pill.
(We recommend: Human trial of new breast cancer vaccine begins).
Pill would prevent severe symptoms and death
Company executives announced Tuesday that their ProfitsThanks to the anticovid vaccine sold to different nations, it would be more than 36 billion dollars in the year. In addition, they hope to break records during 2022 with the production and delivery of the doses.
Added to this, Pfizer could have an increase in its profits due to the anticovid pill that is already in advanced stages of study.
The oral drug, according to information cited by ‘The New York Times’, would prevent serious symptoms or death in patients if taken in the first days after infection.
(You can read: Facebook removes video of Bolsonaro in which he associates vaccines with AIDS).
Angela Hwang, President of ‘Pfizer Biopharmaceuticals Group’, considers that it is a “Lasting opportunity” And, according to his calculations, some 150 million people could make up the market for the pill.
We will have pills even this year if we succeed
He also told the aforementioned media that the governments of different countries would be interested in stocking up on the medicine.
In addition, Albert Bourla, CEO of Pfizer, was hopeful about the results and the advancement of the new drug.
(Read on: Scientists Discover a Method to Block Coronavirus Infection.)
“We hope to have some efficacy studies probably before the end of the year. We already approved a $ 1 billion investment at the end of the summer and we are already in production. We will have pills even this year if we succeed ”, he commented, in a talk with the television network ‘CNBC’.
The multinational Merck, headquartered in Germany, is also manufacturing another pill to combat infection by the new coronavirus SARS-CoV-2.
As is known, it would also prevent death and serious symptoms from the disease.
In October, the company requested authorization from the United States Food and Drug Administration (FDA for its acronym in English). So it is awaiting the advisory committee, which on November 30 will evaluate the studies of the pharmaceutical company and will decide whether or not to approve it for use and sale in the North American country.
(Also read: What is the bombé, the strange drug that leaves ‘zombies’ to its users?).
However, Merck already has trade agreements with other countries such as South Korea, Singapore, New Zealand and Australia, according to the financial media ‘Financial Times’.
Get treatment to people as quickly as possible in certain countries
The company has the capacity to produce more than 10 million tablets in 2021, but it would increase resources, according to the aforementioned media, to manufacture 20 million during 2022.
“We are making these special purchase agreements to get treatment to people as quickly as possible in certain countries,” he claimed Nicholas Kartsonis, vice president of clinical research at Merck.
(You can read: New York Faces Outbreak of Rare Rat-Borne Disease).
Ads are in addition to warnings from the World Health Organization (WHO) that has criticized inequality in access to vaccines.
Based on the agency’s data, reported by the EFE agency, 50 percent of the world’s population has received at least one dose, but most people are from high- and middle-income countries.
– The country is preparing to require a vaccination card in public places.
– China asks families to provide themselves to deal with outbreaks.
– They are investigating a vaccination certificate created in the name of Adolf Hitler.
– She went to the hospital with a toothache and ended up in a coma.
– They sentenced to death a nurse who killed his patients by injecting them with air.
Trends THE WEATHER